TY  - JOUR
AU  - Reig, Anna
AU  - Alvarez-Navascues, Carmen
AU  - Vergara, Mercedes
AU  - Gomez-Dominguez, Elena
AU  - Gallego-Moya, Adolfo
AU  - Perez-Medrano, Indhira M.
AU  - Fabrega, Emilio
AU  - Hernandez-Guerra, Manuel
AU  - Berenguer, Marina
AU  - Estevez, Pamela
AU  - Arencibia, Ana
AU  - Morillas, Rosa M.
AU  - Horta, Diana
AU  - Albillos, Agustin
AU  - Casado, Marta
AU  - De la Cruz, Gema
AU  - Fernandez-Bonilla, Eva
AU  - Molina, Esther
AU  - Hijona, Lander
AU  - Diago, Moises
AU  - Fernandez-Rodriguez, Conrado M.
AU  - Gonzalez-Santiago, Jesus M.
AU  - Sala, Margarita
AU  - Gomez-Camarero, Judith
AU  - Romero-Gomez, Manuel
AU  - Suarez, Francisco
AU  - Vargas, Victor
AU  - Ferre-Aracil, Carlos
AU  - Andrade, Raul J.
AU  - Chahri, Nadia
AU  - Pares, Albert
PY  - 2021
DO  - 10.14309/ajg.0000000000001343
SN  - 0002-9270
UR  - https://hdl.handle.net/10668/24993
T2  - American journal of gastroenterology
AB  - INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information...
LA  - en
PB  - Lippincott williams & wilkins
KW  - Placebo-controlled trial
KW  - Ursodeoxycholic acid
KW  - Biochemical response
KW  - Cirrhosis
KW  - Bezafibrate
KW  - Prognosis
TI  - Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
TY  - research article
VL  - 116
ER  -